-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zamaporvint in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zamaporvint in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zamaporvint in Pancreatic Ductal Adenocarcinoma Drug Details: RXC-004 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zamaporvint in Extrahepatic Bile Duct Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zamaporvint in Extrahepatic Bile Duct Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zamaporvint in Extrahepatic Bile Duct Cancer Drug Details: RXC-004...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zamaporvint in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zamaporvint in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zamaporvint in Metastatic Colorectal Cancer Drug Details: RXC-004 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zamaporvint in Metastatic Biliary Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zamaporvint in Metastatic Biliary Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zamaporvint in Metastatic Biliary Tract Cancer Drug Details: RXC-004...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Etigilimab in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Etigilimab in Sarcomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Etigilimab in Sarcomas Drug Details: Etigilimab (OMP-313M32) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zamaporvint in Gallbladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zamaporvint in Gallbladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zamaporvint in Gallbladder Cancer Drug Details: RXC-004 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibrutinib in Hairy Cell Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibrutinib in Hairy Cell Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibrutinib in Hairy Cell Leukemia Drug Details: Ibrutinib (Imbruvica) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Camrelizumab in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Camrelizumab in Non-Small Cell Lung Cancer Drug Details: Camrelizumab (Airuika) is a humanized monoclonal antibody...
-
Product Insights
Gallbladder Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Gallbladder Cancer - Drugs In Development, 2023’, provides an overview of the Gallbladder Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gallbladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Biliary Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Biliary Tumor - Drugs In Development, 2023’, provides an overview of the Biliary Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Biliary Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...